T2 Biosystems, Inc. now has appointed five new distribution partners in the first half of 2019, allowing its rapid diagnostic technologies, including the T2Bacteria® and T2Candida® Panels, enter into new markets in Estonia, Greece, Ireland, Saudi Arabia and South Africa. In all these countries have approximately 1,170 hospitals that could benefit from T2’s products.

T2 Biosystems’ products are now available in 32 countries outside of the United States, in addition to a direct commercial team in the United Kingdom.

“Our groundbreaking diagnostic panels rapidly detect sepsis-causing bacterial and fungal pathogens directly from whole blood, providing clinically actionable information that can enable changes in patient outcomes. With rapid results, clinicians can ensure their patients are on early and effective therapy, including the de-escalation of unnecessary therapy, which can help address concerns with antimicrobial resistance and hospital costs,” said John McDonough, president and chief executive officer of T2 Biosystems. “Sepsis represents a major threat to global health and these new distribution agreements will enable more patients and clinicians to have access to the benefits of T2 technology. We look forward to adding partners in new geographies in the second half of the year and beyond.”

The T2Bacteria Panel is the first and only FDA-cleared test to identify sepsis-causing bacterial pathogens directly from whole blood in 3 to 5 hours without the need to wait for blood culture, while the T2Candida Panel is the first and only FDA-cleared direct-from-whole blood diagnostic for detection of fungal pathogens that are associated with sepsis. The products are two of several panels that are approved or in development that are run on the Company’s T2Dx® Instrument, which is powered by miniaturized magnetic resonance (T2MR®) technology.